4-Fluorotryptamine (4-FT; developmental code name PAL-551) is a serotonin receptor modulator and monoamine releasing agent of the tryptamine family. It is the 4-fluoro derivative of tryptamine.
The drug acts as a potent full agonist of the serotonin 5-HT2A receptor, with an of 28nM and an of 108%. In addition, it is a serotonin–dopamine releasing agent (SDRA), with values for induction of monoamine release of 108nM for serotonin, 106nM for dopamine, and 1,123nM for norepinephrine in rat brain synaptosomes.
Tryptamines without substitutions at the amine or alpha carbon, such as tryptamine, serotonin (5-hydroxytryptamine; 5-HT), and 5-methoxytryptamine (5-MeO-T), are known to be very rapidly metabolized and thereby inactivated by monoamine oxidase A (MAO-A) in vivo and to have very short elimination half-lives. However, given intravenously at sufficiently high doses, tryptamine is still known to be able to produce weak and short-lived psychoactive effects in humans.
The chemical synthesis of 4-fluorotryptamine has been described.
4-Fluorotryptamine was first described in the scientific literature by 2014.
See also Substituted tryptamine 4-Fluoro-DMT 4-F-5-MeO-DMT 4-F-5-MeO-pyr-T HBL20017 (4-F-5-MeS-DMT)
References
External links 4-Fluorotryptamine - Isomer Design